Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells

Yamamoto Y., Taniguchi T., Inazumi T., Iwamura R., Yoneda K., Odani-Kawabata N., Matsugi T., Sugimoto Y., Shams N.K.

2020
Journal of Ocular Pharmacology and Therapeutics

Therapeutic Area

Glaucoma
Categories

Preclinical development

Affiliations

Research and Development Division, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma-shi, Nara, 630-0101, Japan; Department of Pharmaceutical Biochemistry, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan; Research and Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Research and Development Division, Santen, Inc., Emeryville, CA, United States

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.

Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.

View all Glaucoma publications